Print  Email
Late-Breaking Basic Science 2009

Deadline: Sept. 2, 2009, 5 p.m. CDT

Late-breaking basic science abstracts describe highly meritorious, high impact science. Emphasis will be given to genuine innovation and fundamental, distinctive, novel research.

There is a non-refundable $30 processing fee for each abstract submission.

Rules for Preparation and Submission of Abstracts

  • The presenting author of an accepted abstract must pay a $250 (AHA/ASA member) or $450 (non-member) advance registration fee to attend Scientific Sessions. On-site registration fees are $350 (AHA/ASA member) and $550 (non-member). You must become a member of the AHA by Sept. 30 to receive the reduced registration fee.
  • All other expenses (e.g., airfare, lodging) associated with the submission and presentation of an abstract are the responsibility of the presenter.
  • The American Heart Association Scientific Sessions is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before the date and time of presentation (Nov. 14-18, 2009).
  • Abstract data may not be presented at a national or international meeting or world congress before the date and time of presentation (Nov. 14-18, 2009).  If identical abstracts are accepted for two meetings, one must be withdrawn and AHA staff must be notified. If acceptance of a previously presented abstract is discovered prior to presentation, it will be withdrawn and acceptance of future abstracts will be jeopardized. If dual presentation of identical abstracts is discovered after presentation, the acceptance of future abstracts may be jeopardized and any award associated with the abstract will be withdrawn.

    Exception: If early career investigators want to increase their opportunity of scientific interaction, the abstract submission to the AHA must have incremental information from the abstract submitted elsewhere to justify submission and presentation at the AHA, should the investigator’s work be accepted at both meetings. Each investigator will determine, in good conscience, what constitutes incremental information and should notify AHA staff.
  • Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for the American Heart Association.

There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed.

Embargo Policy
Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.

Abstract Title
An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Author Name(s)

  • The submitting author is designated as the primary/presenting author. You may rearrange the order of the authors; however, always list the senior author last.
  • If an author's name appears on more than one abstract, it must be identical on each abstract.
  • Additions or deletions of author names are not permitted after Sept. 2, 2009, 5 p.m. CDT.

Abstract Data

  • Submit all abstracts in English.
  • Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
  • Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
  • Proofread abstracts carefully to avoid errors before submission.  The abstract will be published exactly as it has been submitted – NO EXCEPTIONS.

Abstract Text

  • Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
  • Use generic drug names.
  • Do not begin sentences with numerals.
  • Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
  • Do not include references, credits or grant support.
  • Do not include the names or personal information of any patient participating in the study or trial.
  • Abstracts are limited to 1,950 characters (about 300-350 words). This includes the text plus any graphic/table, but not the title or authors. Addition of a table deducts 250 characters; addition of a graphic deducts 500 characters. Spaces do not count as characters.
  • The format for the Circulation Research supplement allows graphics/tables to be placed anywhere within the abstract. Do not add paragraph breaks within the body of the abstract.

Abstract Revisions

After the Sept. 2, 2009, 5 p.m. CDT deadline, abstracts may not be revised in any way or resubmitted. Proofread abstracts carefully to avoid errors before submission. If accepted, your abstract will be published as submitted.

Abstract Acceptance

  • Abstract grading is blinded and abstracts are selected on the basis of scientific merit.
  • Abstract acceptance/non-acceptance status will be available the end of September.  Please ensure that the email provided is accurate as all correspondences will be sent via e-mail.
  • Accepted abstracts will be published in the Dec. 4, 2009 issue of Circulation Research: Journal of the American Heart Association.

Presentation

  • If you do not want your abstract to be scheduled as an oral presentation, select “Poster Presentation only” under presentation format preference in the abstract submitter.
  • All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
  • No person may record any portion of the AHA Scientific Sessions, scientific conferences and Stroke Conference, whether by video, still or digital photography; audio; or any other recording or reproduction mechanism. This includes recording of presentations and supporting A/V materials and of poster presentations and supporting poster materials.

Furthermore, science information shared by investigators at the time of a meeting is confidential and often unpublished data. Taking photos of or recording the content of meeting room slides is also prohibited, and is considered intellectual piracy and unethical. Attendees who ignore this policy will be asked to leave the educational session and are at risk of losing their badge credentials. 

The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

  • The AHA reserves the right to all video or audio recordings of presentations at the 2009 Scientific Sessions.
  • All oral presentations must be in electronic format. Submit electronic presentations to the American Heart Association six hours before the session starts. Instructions for presentation upload will be provided upon acceptance.


View Late-Breaking Basic Science Abstracts in Circulation Research.